US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Neuroscience

2.44

-0.0150-0.61%

Volume:127.17K

Turnover:310.63K

Market Cap:65.92M

PE:-0.98

High:2.54

Open:2.49

Low:2.33

Close:2.45

Loading ...

Overview Company News Filings

BRIEF-Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker

Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

THOMSON REUTERS

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Promising US Penny Stocks To Watch In February 2025

Simply Wall St.

Pleasing Signs As A Number Of Insiders Buy Alto Neuroscience Stock

Simply Wall St.

Promising Outlook for Alto Neuroscience with ALTO-300’s Phase IIb Success Reinforcing Buy Rating

BRIEF-Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial

Alto Neuroscience Announces Favorable Outcome From Interim Analysis of Alto-300 Phase 2B Major Depressive Disorder Trial

THOMSON REUTERS

Alto Neuroscience Inc -Topline Results Are Expected in Mid-2026

THOMSON REUTERS

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Stifel Nicolaus Sticks to Their Buy Rating for Alto Neuroscience, Inc. (ANRO)

BRIEF-Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million

Alto Neuroscience : Sales Agreement Prospectus Covering Offering of up to $75 Mln Common Stock That May Be Offered From Time to Time

THOMSON REUTERS

Alto Neuroscience Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing

THOMSON REUTERS

BRIEF-Alto Neuroscience Amends Loan And Security Agreement

Alto Neuroscience Inc - Amends Loan and Security Agreement

THOMSON REUTERS

Alto Neuroscience Inc - Maturity Date Extended to January 1, 2029

THOMSON REUTERS

Alto Neuroscience Inc - Maximum Term Loans Increased to $75 Million

THOMSON REUTERS

All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy

Alto Neuroscience Initiated at Buy by Jones Trading

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANRO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience","latestPrice":2.435,"timestamp":1746215863848,"preClose":2.45,"halted":0,"volume":127169,"delay":0,"floatShares":19503522,"shares":27072129,"eps":-2.496992,"marketStatus":"Trading","change":-0.015,"latestTime":"05-02 15:57:50 EDT","open":2.4886,"high":2.54,"low":2.33,"amount":310633.2492214,"amplitude":0.085714,"askPrice":2.44,"askSize":235,"bidPrice":2.43,"bidSize":312,"shortable":3,"etf":0,"ttmEps":-2.496992,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746216000000},"marketStatusCode":2,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":2.45,"preHourTrading":{"tag":"盘前","latestPrice":2.5599,"preClose":2.45,"latestTime":"08:25 EDT","volume":51,"amount":124.059897,"timestamp":1746188757776},"postHourTrading":{"tag":"盘后","latestPrice":2.46,"preClose":2.45,"latestTime":"19:55 EDT","volume":2621,"amount":6423.2601,"timestamp":1746143735380},"volumeRatio":0.854195,"impliedVol":1.8281,"impliedVolPercentile":0.2564},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":19503522,"roa":"-32.46%","roe":"-55.19%","lyrEps":-2.496992,"volumeRatio":0.854195,"shares":27072129,"dividePrice":0,"high":2.54,"amplitude":0.085714,"preClose":2.45,"low":2.33,"week52Low":1.6,"pbRate":"0.44","week52High":17.55,"institutionHeld":0,"latestPrice":2.435,"committee":0.140768,"eps":-2.496992,"divideRate":0,"volume":127169,"delay":0,"ttmEps":-2.496992,"open":2.4886,"prevYearClose":4.23,"prevWeekClose":2.35,"prevMonthClose":2.49,"prevQuarterClose":2.16,"fiveDayClose":2.35,"twentyDayClose":1.85,"sixtyDayClose":4.2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512856064","title":"BRIEF-Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2512856064","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512856064?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:08","pubTimestamp":1739977692,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram BiomarkerFeb 19 (Reuters) - ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA2MLZKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":1},{"id":"2512270101","title":"Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2512270101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512270101?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:03","pubTimestamp":1739970180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA2MLZKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2512101274","title":"Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101274","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101274?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:03","pubTimestamp":1739970180,"startTime":"0","endTime":"0","summary":"– Patent supports Alto’s precision approach to improve patient selection –。ALTO-300, also known agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist and is being developed as an adjunctive treatment in the United States for biomarker-characterized patients with MDD who have had an inadequate response to current standard of care antidepressants.\"The granting of this patent underscores our novel approach to patient selection in neuropsychiatric treatment using objective biomarkers,\" said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. \"We are dedicated to developing more effective, targeted treatments for patients with MDD and deepening our understanding of the patient phenotype that is most likely to benefit, based on our unique ALTO-300 biomarker.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-announces-u-patent-130300698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4138","ABVC","BK4139","BK4109","ANRO","ALTO"],"gpt_icon":0},{"id":"2512219107","title":"Promising US Penny Stocks To Watch In February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512219107","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512219107?lang=en_us&edition=fundamental","pubTime":"2025-02-19 04:11","pubTimestamp":1739909466,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a mixed trading environment with major indexes slipping after recent gains, investors are keenly observing opportunities that might arise from smaller segments of the market. Penny stocks, often representing smaller or newer companies, remain relevant for their potential to offer significant returns when backed by solid financials. In this article, we will explore several penny stocks that stand out due to their financial strength and growth potential, providing an intriguing option for those looking to uncover hidden value in today's market landscape.Overview: Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company dedicated to developing covalent small molecule drugs for genetically defined cancers and metabolic diseases, with a market cap of $135.17 million.Operations: Biomea Fusion, Inc. currently does not report any revenue segments as it is focused on developing covalent small molecule drugs for specific cancers and metabolic diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promising-us-penny-stocks-watch-201106877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMEA","IGMS","BK4021","PVL","BK4209","SB","BK4007","BABB","ANRO","PHX","BK4213","BK4539","BK4139","BK4563","BK4585"],"gpt_icon":0},{"id":"2512163381","title":"Pleasing Signs As A Number Of Insiders Buy Alto Neuroscience Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2512163381","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512163381?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:48","pubTimestamp":1739886499,"startTime":"0","endTime":"0","summary":"It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Alto Neuroscience, Inc.'s  case, it's fantastic news for shareholders.While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.The Last 12 Months Of Insider Transactions At Alto Neuroscience. The Chief Medical Officer Adam Savitz made the biggest insider purchase in the last 12 months. That single transaction was for US$191k worth of shares at a price of US$13.22 each. So it's clear an insider wanted to buy, even at a higher price than the current share price . While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at ab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pleasing-signs-number-insiders-buy-134819381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2511613471","title":"Promising Outlook for Alto Neuroscience with ALTO-300’s Phase IIb Success Reinforcing Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613471","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511613471?lang=en_us&edition=fundamental","pubTime":"2025-02-15 01:35","pubTimestamp":1739554532,"startTime":"0","endTime":"0","summary":"Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), retaining the price target of $18...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-alto-neuroscience-with-alto-300s-phase-iib-success-reinforcing-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-alto-neuroscience-with-alto-300s-phase-iib-success-reinforcing-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALTO","ANRO"],"gpt_icon":0},{"id":"2510379031","title":"BRIEF-Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2510379031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510379031?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:14","pubTimestamp":1739366053,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder TrialFeb 12 (Reuters) - Alto Neuroscience ANRO.N:ALTO NEUROSCIENCE ANNOUNCES FAVORABLE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P311X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2510796383","title":"Alto Neuroscience Announces Favorable Outcome From Interim Analysis of Alto-300 Phase 2B Major Depressive Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2510796383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510796383?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:03","pubTimestamp":1739365385,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P311X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2510379632","title":"Alto Neuroscience Inc -Topline Results Are Expected in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2510379632","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510379632?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:03","pubTimestamp":1739365385,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P311X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2510371501","title":"Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371501","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371501?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:03","pubTimestamp":1739365380,"startTime":"0","endTime":"0","summary":"– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –。MOUNTAIN VIEW, Calif., February 12, 2025----Alto Neuroscience, Inc.  , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for patients with major depressive disorder . Based on the results of the interim analysis, the Phase 2b trial will continue with an increase of approximately 50 biomarker positive patients in the final analysis sample. Topline results are expected in mid-2026.Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform measures brain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-announces-favorable-outcome-130300392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANRO","BK4109","ALTO","BK4138","BK4007"],"gpt_icon":0},{"id":"2510851164","title":"Stifel Nicolaus Sticks to Their Buy Rating for Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510851164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510851164?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191539,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-alto-neuroscience-inc-anro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-alto-neuroscience-inc-anro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","ANRO"],"gpt_icon":0},{"id":"2508176303","title":"BRIEF-Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2508176303","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508176303?lang=en_us&edition=fundamental","pubTime":"2025-02-04 06:06","pubTimestamp":1738620408,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Files For Mixed Shelf Of Up To $300 MillionFeb 3  - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILINGALTO NEUROSCIENCE : SALES AGREEMENT PROSPECTUS COVERING OFFERING OF UP TO $75 MILLION COMMON STOCK THAT MAY BE OFFERED FROM TIME TO TIMESource text: [ID:n0001193125-25-019267]Further company coverage: ANRO.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2508178990","title":"Alto Neuroscience : Sales Agreement Prospectus Covering Offering of up to $75 Mln Common Stock That May Be Offered From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508178990?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:08","pubTimestamp":1738616890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0WF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2508178573","title":"Alto Neuroscience Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178573","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508178573?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:08","pubTimestamp":1738616890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2503399969","title":"BRIEF-Alto Neuroscience Amends Loan And Security Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2503399969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503399969?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:59","pubTimestamp":1737032355,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Amends Loan And Security AgreementJan 16  - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE INC - AMENDS LOAN AND SECURITY AGREEMENTALTO NEUROSCIENCE INC - MATURITY DATE EXTENDED TO JANUARY 1, 2029ALTO NEUROSCIENCE INC - MAXIMUM TERM LOANS INCREASED TO $75 MILLIONFurther company coverage: ANRO.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2503993828","title":"Alto Neuroscience Inc - Amends Loan and Security Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2503993828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503993828?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:03","pubTimestamp":1737028989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2503993825","title":"Alto Neuroscience Inc - Maturity Date Extended to January 1, 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2503993825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503993825?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:03","pubTimestamp":1737028989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC02D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2503938229","title":"Alto Neuroscience Inc - Maximum Term Loans Increased to $75 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2503938229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503938229?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:03","pubTimestamp":1737028989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC02D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2502570147","title":"All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2502570147","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502570147?lang=en_us&edition=fundamental","pubTime":"2025-01-09 01:00","pubTimestamp":1736355613,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc.  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.As such, the Zacks rating upgrade for Alto Neuroscience, Inc. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Alto Neuroscience, Inc. imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-alto-neuroscience-inc-anro-170013078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANRO"],"gpt_icon":0},{"id":"2491169544","title":"Alto Neuroscience Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2491169544","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491169544?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:21","pubTimestamp":1734355260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 08:21 ET (13:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2025-05-01","current":-1.097322,"percent":0.921233,"low":-16.978804,"twenty":-10.422558,"median":-6.046215,"eighty":-1.752096,"high":-0.793245,"avg":-5.753829,"sd":4.071533,"marketCap":67409601},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290},{"date":"2025-04-25","current":-1.004777,"twenty":-10.431438,"median":-6.11117,"eighty":-1.798105,"marketCap":61724454},{"date":"2025-05-01","current":-1.097322,"twenty":-10.422558,"median":-6.046215,"eighty":-1.752096,"marketCap":67409601}],"updateTime":1746215870818}}}